Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Inventions of Dr. Shamir Israel Lebovitz

 

• USA Patent No 5,993,180

the use of substance or composition for use in induction labour in female mammals issed nov 1999

 

• Canadian Patent No 2,171,903

the use of substance or compostion for induction of labour in female mammals.

 

• European Patent No 96202193,7

A substance or composition for use in a method of treatment of female mammals

 

• Israel Patent No 122278

a method and pharmaceutical composition for inhibiting premature ripening of fetal memmbranes and preterm

Labour in Mammals.

 

Shamir Israel Lebovitz, M.D. FCOG (Israel & SA)

Business Address: 27 Emeck Bracha Street, Tel Aviv, Israel

Telephone: W: 052-790-3203 H: 972-3-695-9717
Cell Phone: 972 54-537-5565
e-mail: smorshar100@gmail

 

We are developing new Biological immunological product to induce labor as to prevent Preterm labor with a new device that will inject the compounds into the cervix

PATENTS

 

USA Patent No 5, 993,180 for the use of substance or composition for use in induction labor in female mammals issued November 1999

 

Canadian Patent No 2, 171,903 for the use of substance or composition for induction of labor in female mammals DATE 2007

 

European Patent No 96202193,7 a substance or composition for use in a method of treatment of female mammals DATE 2007

 

Israel Patent No 122278 a method and pharmaceutical composition for inhibiting premature ripening of fetal membranes and preterm labor in mammals. DATE 2002

 

USA, European, Indian, & Israeli RU National phase PATENT No. _____APPLICATION MULTI-DIRECTIONAL NEEDLE; OUR REF: 332-L-03-RU for use in Induction of labor in as well Prevention of Preterm Labor; With the Biological Product immunological product for Induction as well prevention of preterm labor Issued:   Until 2031

 

Employment

 

Edith Wolfson Medical Center, Holon

2014

Self-employed independent Fetal Ultrasound Consultant

1990 – Present

 

Telerescue 

2010 – Present

CEO & Co-Founder

www.telerescue.co.il

 

Bioterm Pharmaceuticals Ltd.

2012 – Present

CEO & Co-Founder

http://www.bio-term.com/

 

Machon Mor Sonography  

2000 – 2002

Rabin Medical Centre

1998 – 2000

 

Tel-Aviv University

Sackler Medical School

Department of Obstetrics and Gynecology

Specialist: Fetal Ultrasound

 

Belinson Hospital

1997 – 1999

Department of OB, Sonography Unit

Petah Tikva, Israel

 

Mayanei HaYeshua Medical Center        

1996 – 1998

Department of Obstetrics and Gynecology

Specialist: OBGYN

Bnei Brak, Israel

 

Edenvale Hospital  

1995 – 1996

Witwatersrand University Medical School

Department of Obstetrics and Gynecology

Specialist: OBGYN

Cape Town, South Africa

 

Bararwana Hospital           

1991 – 1995

Training for Fellowship F.C.O.G

Family Planning Clinic (In charge: Prof. Van Gelderen)

Johannesburg, South Africa

 

The Sheba Medical Center, Tel-Aviv University Affiliation

1988 – 1991

Israel’s National Medical Center

Department of Obstetrics and Gynecology

Residency OB/GYN

 

University of Rome

1980 – 1983

 

Sackler Medical School    

1983 – 1986

Medical School

Tel Aviv University

Ramat Aviv, Israel

 

Rabin Medical Center 

1987 – 1989

Beilinson Hospital

Petah Tikva, Israel

Internship: Family Medicine

 

Boards

 

1995 F.C.O.G (Israel) Fellow of the College of Obstetricians and Gynaecologists, Israel

 

1986 F.C.O.G (South Africa) Fellow of the College of Obstetricians and Gynaecologists, South Africa

 

1987 M.D (Israel) Sackler Medical School, Tel Aviv University, Israel

 

Clinical Experience

 

1996 – Present

Senior specialist in Department of Ob/Gyn, (Tertiary Centre) Rabin Medical Centre, Bellinson Campus, Sackler Medical School, Tel Aviv University, Israel

 

1994 – 1996

Head of Department of Ob/Gyn, Edenvale Hospital, Medical School, Witwatersrand University, South Africa (see job description No4) Master’s Thesis: Advanced intra-abdominal pregnancy presenting as antepartum hemorrhage Supervisor: Professor Vangelderen, Chairman of Department of Obstetrics and Gynecology, Witwatersrand Medical School, South Africa.

 

1991 – 1994

Residency:            Department of Ob/Gyn, Medical School, University of Witwatersrand, South Africa

 

Coordinating and teaching under graduate medical student fourth, fifth and sixth years, post graduate training for first to sixth year registrar programme, in charge of the tuition programme for part 1 and 2 fellowship examination in 0 & G. (See Job Description No2)

 

1988 – 1991

Residency:            Department of Ob/Gyn Tel –Hashomer {SHIBA}; Hospital, Affiliated:Tel-Aviv University.

 

1987 – 1989

Family Medicine: Family Planning, Office Gynaecology, Menopausal diagnosis and treatment seeing twenty patients a day in the Family Medicine Centre, Rabin Medical Campus, (Tertiary Hospital), Tel Aviv University, Sackler Faculty of Medicine

 

Certifications

 

1987          MD Sackler Medical School,,Tel Aviv University, Israel

1996          F.C.O.G – (SA)-Fellow of the College of Obstetricians Gynaecologists of South Africa.

1995          F.C.O.G – (ISR) Fellow of the College of Obstetricians Gynaecologists of Israel

1996          Obstetrics and Gynecology Degree: March 1996 F.C.O.G [S.A]

 

Clinical Procedures                            

1988 – Present

Gynecology: Number of Procedures or Hours

Dilatation and curettage – Diagnostic and Therapeutic:  900

Laparoscopies – Diagnostic and Surgical  300

Total abdominal hysterectomies + BSO:   370

Laparotomies (ectopic, pelvic inflammatory disease and ovarian pathology):  750

Vaginal hysterectomies:  160

Anterior and posterior repairs and vault repairs:  450

Wertheim procedures and radical hysterectomy: 18

Tubal Surgery – Micro Surgery: 180

Cone biopsy – Diagnostic and Therapeutic:  60

Sterilizations – Mini laparotomy, Laparoscopy:  1100

Colposcopies: 400

Hysteroscopy Diagnostic: 155

Endoscopy: 30

Endometrial ablation (Laser Procedures):

• Burch + M.M.K: 25
• Raz Procedure: 20
• Vaginal Probe Scans:  5000
• Intra-cavitary Cesium Insertion: 100

Uro-gynecological Clinic:  300

Menopausal Clinic:  500

Reproductive Endocrinology Clinic:  300

Gynecological Oncological Clinic and Ward:  6

Obstetrics:

Normal Vaginal Deliveries:  3850

Forceps Deliveries: 400

Vaginal Twin Deliveries 150

Vacuum Extractions: 250

External Cephalic Versions: 50

Partial Breech Extractions: 20

Assisted Breech Delivery: 100

Caesarean Section: 900

Caesarean Section/Hysterectomy: 25

High-Risk Ante-Natal Clinic:  600 hours

Diagnostic Amniocentesis: 150 cases

Sonography:

Obstetrical Antenatal Assessment:  900 hours

Gynecology Assessments: 4600 hours

Infertility Clinic: Work up, ovulation induction, (Clomid, Pergonal)

Preparation for IVF and GIFT:  500 Cases

Cytology (PAP Smear Readings):  350 Cases

 

Membership in Professional Associations

(Various Ob/Gyn Societies in South Africa, Israel and America)

 

1997 – 2012            The Ultrasound Society of Israel

 

1988  The Infertility Society of Israel

 

1988  The Medical and Dental Council, Israel

 

1988  Israel Medical Association

 

1991  The Medical and Dental Council of South Africa

 

1991   The College of Medicine, South Africa

 

1991   The Medical Association of South Afria

 

1991   The Statistics Committee of the Department of Obstetrics and Gynaecology of the University of Witwatersrand, South Africa

 

1991   Oncology Group Department of Obstetrics and Gynaecology, University of Witwatersrand, South Africa

 

1991   The Southern Transvaal Branch of the South African Society of Obstetrics and Gynaecologists

 

1991   The College of Obstetricians and Gynaecologists, South Africa

 

1991   The Infertility Society of South Africa

 

1997    The College of Obstetricians and Gynaecologists, Israel

 

1991 Termination of Pregnancy Committee, J.G Strijdon Hospital, South Africa

 

1991 The Drug Tender Board Committee, J.Gstrijdon Hospital, South Africa.

 

1991   The Ethical Committee, Department of Obstetrics and Gynaelcology

University of Witwatersrand, South Africa

 

 

Languages: English, Italian, and Hebrew

 

Hobbies: Tennis, jogging, traveling,

 

Bioterm Pharmaceutical Ltd.

 

Revolution in treatment for pre-term labor and induction of labor that affect millions of women
and newborn each year!

Bioterm Pharmaceuticals Ltd. is the developer of novel therapeutics for the treatment and prevention of pre-term labor and for the induction of labor that cause severe morbidity of millions of newborn worldwide.

The Company has patented the use of two molecules, its Preventerm molecule for the prevention of pre-term labor (PCT, pending) and its Inducterm molecule (approved patent) for labor induction, which are both multi-hundred million dollar markets.

Both molecules have been approved for therapy for unrelated indications, allowing BT a substantial acceleration of regulatory approvals. BT is currently seeking an equity investment of $ 7-9 million to complete Phase II clinical trials for Preventerm and pre-clinical trials for Inducterm, to broaden management, and to enhance marketing and business development activities in the U.S. and Europe.

 

The Mission:

To revolutionize pre – term labor and labor induction treatments which affect millions of women and newborn each year – globally

BT is developing novel and advanced products for two major medical indications in multi-hundred million-dollar markets. The Company’s mission is to become a leader in the development of obstetric pharmaceuticals, to improve healthcare delivery for patients, doctors and hospitals, and to provide an attractive return on investment for its shareholders and benefits for its strategic partners. Longer term, the

Company intends to apply its technology to additional lucrative markets such as veterinary obstetrics and to develop products for more OB/Gyn indications.

The Company was founded in 2002 by Dr. Israel Shamir Leibovitz MD, FCOG, a highly acclaimed gynecologist and prolific inventor, who functions as Chief Medical Officer and interim CEO; Prof. Eliezer Shalev, Director of clinical trials, chairman of the Department of Obstetrics and Gynecology of Haemek Hospital in Afula, Israel; and Prof. Daniel S. Seidman, MD, M.Sc, Associate Director of clinical trials and NIH grant application. Prof. Seidman is currently a Senior Physician and Associate Clinical Professor at the Sackler School of Medicine at Tel-Aviv University and one of the most fruitful Israeli medical researchers, with more than 400 publications.

BT is further augmented by highly esteemed scientific leaders in obstetrics in Europe and the U.S.: Prof. Robert L. Goldenberg, Co-Director of the Center for Research in Women’s Health at the University of Alabama (UAB) and formerly the Chairman of the Department of Obstetrics and Gynecology; Prof. Phillip Robert Bennett, MD, PhD, FRCOG, a Professor in Obstetrics and Gynaecology at the Imperial College School of Medicine, Institute of Obstetrics; Prof. Emile Papiernik, Chairman of the Department of Obstetrics and Gynecology at the Hôpital Cochin, Paris; and Dr. Joseph Blankstein, the Chairman of the department of obstetrics and Gynecology at Mount Sinai Hospital Medical Center in Chicago, Illinois. [CV’s available upon request.]

BT is currently seeking an equity investment of $6-$8 million to complete Phase II clinical trials for Preventerm and pre-clinical trials for Inducterm, to broaden management, and to enhance marketing and business development activities in the U.S. and Europe.

SOURCE

http://www.bio-term.com/